Joyce Reyes - 10 Mar 2023 Form 4/A - Amendment Insider Report for Histogen Inc.

Role
Officer
Signature
/s/ Susan A. Knudson as attorney-in-fact for Joyce Reyes
Issuer symbol
N/A
Transactions as of
10 Mar 2023
Net transactions value
$0
Form type
4/A - Amendment
Filing time
28 Apr 2023, 18:56:26 UTC
Date Of Original Report
14 Mar 2023
Previous filing
03 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HSTO Stock Option (right to buy) Award $0 +47,417 $0.000000 47,417 10 Mar 2023 Common Stock 47,417 $0.9500 Direct F1
transaction HSTO Stock Option (right to buy) Award $0 +16,659 $0.000000 16,659 10 Mar 2023 Common Stock 16,659 $0.9500 Direct F1, F2
transaction HSTO Stock Option (right to buy) Disposed to Issuer $0 -1,200 -100% $0.000000* 0 10 Mar 2023 Common Stock 1,200 $4.80 Direct F3, F4, F5
transaction HSTO Stock Option (right to buy) Disposed to Issuer $0 -4,452 -100% $0.000000* 0 10 Mar 2023 Common Stock 4,452 $4.80 Direct F3, F4, F6
transaction HSTO Stock Option (right to buy) Disposed to Issuer $0 -7,833 -100% $0.000000* 0 10 Mar 2023 Common Stock 7,833 $3.20 Direct F3, F4, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the shares subject to the option vest one year after the date of grant, on 3/10/2024, and the remaining 1/36 of the shares vest on a monthly basis thereafter.
F2 The shares subject to this option are subject to forfeiture in the event that the shares available pursuant to the Plan are not increased prior to the one-year anniversary and vesting of the award by an amount required to be available for issuance for all outstanding stock awards containing this forfeiture condition.
F3 Effective June 2, 2022, the Issuer effected a 1-for-20 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share.
F4 On March 10, 2023, the Issuer and the Reporting Person agreed to cancel the stock option award.
F5 1/4 of the shares subject to the option vested on 9/15/2022 and the remaining 1/36 of the shares vest on a monthly basis thereafter.
F6 1/4 of the shares subject to the option vested on 11/8/2022 and the remaining 1/36 of the shares vest on a monthly basis thereafter.
F7 1/4 of the shares subject to the option vest one year after the date of grant, on 6/1/2023, and the remaining 1/36 of the shares vest on a monthly basis thereafter.

Remarks:

Senior Vice President of Regulatory, Quality, Clinical Operations, and Technical Operations This Form 4/A amends the Form 4 filing made on behalf of the Reporting Person on March 14, 2023. The Form 4, as originally filed, inadvertently omitted the cancelled stock option grant of 4,452 shares.